

# Panayiota Papasavva, MD, MSc, PhD

|                         |  |                    |
|-------------------------|--|--------------------|
| <b>CURRENT POSITION</b> | Haematologist, The Cyprus Institute of Neurology and Genetics (CING), Cyprus   | April 2023–present |
| <b>PERSONAL DETAILS</b> | Address: Dodekanissou 66, 4043, Limassol<br>Mobile: +357 99888335<br>Email: <a href="mailto:panayiotap@cing.ac.cy">panayiotap@cing.ac.cy</a><br>ORCID ID: 0000-0003-4410-3119  |                    |
| <b>WORK EXPERIENCE</b>  | Haematologist, CING, Cyprus  | April 2023–present |
|                         | Postdoctoral research on “Preclinical validation of HBIVSI-110(G>A)-specific gene editing as advanced therapy for thalassemia”, MGTD, CING, Cyprus   | Feb 2022–Mar 2023  |
|                         | PhD research work on “Genome-editing-mediated lineage-specific knockdown of disease modifiers as therapy of $\beta$ -haemoglobinopathies”, MGTD, CING, Cyprus  | 2017–2021          |
|                         | Consultant Haematologist, Ygia Polyclinic Private Hospital, Limassol, Cyprus   | 2014–2015          |
|                         | Blood Transfusion Centre, Haematology residency, G. Gennimatas Hospital, Athens, Greece  | Sep 2012– Mar 2013 |
|                         | Laboratory of Haematology, Haematology residency, G. Gennimatas Hospital, Athens, Greece   | Mar 2011– Sep 2012 |
|                         | Haematology Clinic, Haematology residency, G. Gennimatas Hospital, Athens, Greece  | Sep 2010– Mar 2011 |
|                         | Haematology Department, Haematology residency, 3rd University Internal Medicine Clinic, GHTDA “Sotiria” Hospital, Athens, Greece   | Dec 2008– Jun 2010 |
|                         | Internal Medicine, residency GHA Korgialenio – Benakio Hospital, Athens, Greece  | May 2004– Jun 2006 |
|                         | Pre-registration, Larnaca General Hospital, Cyprus   | 2002–2003          |
|                         | Rural general physician, General Hospital Krestena, Elis, Greece   | 2000–2002          |
| <b>EDUCATION</b>        | PhD in Medical Genetics, CING, Cyprus  | 2017–2021          |
|                         | MSc in Medical Genetics awarded with Distinction, CING, Cyprus   | Sep 2017           |
|                         | Title of medical specialty in Haematology, Public health department, Attica domain, Greece   | Nov 2013           |
|                         | Medical Degree awarded with Distinction, Medical School of National and Kapodistrian University of Athens, Greece  | Jun 2000           |
|                         | Apolytirio 20/20, Secondary Education, Lykeion Makariou III, Larnaca   | Jun 1994           |
| <b>MEMBERSHIPS</b>      | Hellenic Society of Gene Therapy and Regenerative Medicine<br>Cyprus Society of Human Genetics<br>Cyprus Medical Association<br>Cyprus Society of Haematology<br>Hellenic Society of Haematology<br>Cyprus Biological Society<br>European Hematology Association |                    |

---

## HONORS

### Scholarships

A. G. Leventis Foundation grant 2020–2021

Eurobank PhD Student grant “Genome-editing-mediated lineage-specific knockdown of disease modifiers as therapy of  $\beta$ -Globinopathies” for the time period Sep 2017 to Aug 2020

Eurobank MSc Student grant for the academic year 2016–2017

6-year Medical School Scholarship by the State Scholarships Foundation I.K.Y (full scholarship)

### Awards

Highest ranking student award for the academic years 2016–2017 and 2017–2018, CING, Cyprus.

Award of excellence, 2000, Medical School of National and Kapodistrian University of Athens, Greece.

**Best Poster Award, 1st Prize. Panayiota L. Papasavva**, Petros Patsali, Constantinos C. Loucari, Lola Koniali, Nikoletta Y. Papaioannou, Basma Naissheh, Marina Kleanthous, and Carsten W. Lederer, *Exploring miRNAs as tools for therapy: Tag-activated microRNA-mediated endogene deactivation (TAMED)*, 9<sup>th</sup> IMBMC congress, Nov 18<sup>th</sup> to 20<sup>th</sup>, 2021, Nicosia, Cyprus. **Poster.**

**Best Poster Award, 1st Prize.** Lederer CW, Patsalis P, **Papasavva P**, Stephanou C, Turchiano G, Romito M, Christou S, Sitarou M, Mussolino C, Cornu TI, Antoniou MN, Cathomen T, Kleanthous M. 07/11/2019 *Getting personal: mutation-specific gene editing and addition strategies for  $\beta$ -thalassemia and beyond*. 7th International Multithematic Bio-Medical Congress, Nicosia, Cyprus. **Poster and Oral Presentation.**

**CSHG&ESHG National Fellowship Award.** Patsalis P, Turchiano G, **Papasavva P**, Romito M, Loucari CC, Stephanou C, Christou C, Sitarou M, Mussolino C, Cornu TI, Antoniou MN, Lederer CW†, Cathomen C, Kleanthous M. 15/06/2019 *Safe and efficient personalised TALEN- and CRISPR/Cas9-based gene correction therapy for  $\beta$ -thalassaemia by non-viral delivery to primary cells*. European Society of Human Genetics 52nd Annual Conference, Gothenburg, Sweden. **Oral Presentation.**

**3rd Prize for Best Poster. Papasavva P**, Patsali P, Loucari C, Obaid M, Stais E, Lederer CW, Kleanthous M. 17/11/2018 *CRISPR/Cas9-based disruption of beta-thalassemia disease modifiers*. 6th International Multithematic Bio-Medical Congress, Nicosia, Cyprus. **Poster.**

**George Stamatoyiannopoulos Prize for best original research.** Patsali P, **Papasavva P**, Romito M, Turchiano G, Loucari C, Stephanou C, Christou S, Sitarou M, Cornu TI, Mussolino C, Antoniou MN, Cathomen T, Lederer CW, Kleanthous M. 02/06/2018 *CRISPR/Cas9 and TALEN-mediated disruption of aberrant splice site restores normal gene function*. 3rd Congress of the Hellenic Society for Gene Therapy and Regenerative Medicine, Thessaloniki, Greece. **Oral Presentation.**

---

## GRANT WRITING

Co-authorship of RESTART PROGRAMMES 2016–2020 EXCELLENCE HUBS\_EXCELLENCE/0432/0086 (funded with 200.000 EURO)

Co-authorship of RESTART PROGRAMMES 2016–2020 EXCELLENCE HUBS\_EXCELLENCE/0421/0320 (not funded)

Co-authorship of RESTART PROGRAMMES 2016–2020 EXCELLENCE HUBS\_EXCELLENCE/0421/0066 (not funded)

Authorship of Cooley’s Anemia Foundation Research Fellowship 2020– 2021 (not funded)

---

|   |  |
|---|--|
| <b>COMMUNICATION AND EDUCATION SKILLS</b> | <p>Faculty Associate for the Academic Year 2022–2023, CING</p> <p>Lectures within MM101 – Molecular Basis of Monogenic Diseases course context, CING</p> <p>Laboratory supervision of PhD, MSc students and summer interns at MGTD of CING (2017–2023)</p> <p>Language skills</p> <ul style="list-style-type: none"> <li>• English: Proficient</li> <li>• Greek: Native</li> </ul> |
|---|--|

---

|                                 |  |   |
|---------------------------------|--|---|
| <b>SEMINARS AND CONFERENCES</b> | <p>Inherited and acquired bone marrow failures in children and adolescents, Pediatric Hospital – IRCCS Institute Giannina Gaslini, Genoa, Italy, 16–19 Jan 2023<br/>(Coordinated by prof Carlo Dufour, Chair Hemato-Oncology Department and of Hematology Unit)</p> <p>Rare hereditary haemolytic anaemia in laboratories, Federico II University of Naples, CEINGE- Advanced Biotechnologies, Naples, Italy, 20–22 July 2022<br/>(Coordinated by Prof. Achille Iolascon, Professor of Medical Genetics, Dept. of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, President, of the Italian Society of Human Genetics)</p> <p>Introduction to Molecular Biosciences, preparatory course, CING, Cyprus (15 hours)</p> <p>Two-year training programme (courses and lectures) of Hellenic Society of Haematology, Athens, Greece</p> <p>Summer School of the Foundation of Hellenic Society of Haematology (training in state-of-the-art molecular techniques and Hodgkin Lymphoma), Alexandroupoli, Greece (25 hours)</p> <p>FISH technique in Diagnostic Haematology, Department of Molecular Cytogenetics, G. Gennimatas Hospital, Athens, Greece (40 hours)</p> <p>Molecular techniques in Diagnostic Haematology, Research laboratory, General University Hospital Laiko, Athens, Greece (40 hours)</p> <p>Participation in numerous international and domestic medical and genetics conferences</p> | <p>Jan 2023</p> <p>July 2022</p> <p>Sep 2015</p> <p>2012–2013</p> <p>May 2012</p> <p>Jun 2012</p> <p>Nov 2011</p> |
|---------------------------------|--|---|

---

|                                       |  |
|---------------------------------------|--|
| <b>PUBLICATIONS AND PRESENTATIONS</b> | <p><i>Peer-reviewed articles</i></p> <p><i>High-efficiency editing in hematopoietic stem cells and the HUDEP-2 cell line based on in vitro mRNA synthesis.</i><br/>Nikoletta Papaioannou, Petros Patsali, Basma Naiisseh, <b>Panayiota L Papisavva</b>, Lola Koniali, Ryo Kurita, Yukio Nakamura, Soteroula Christou, Maria Sitarou, Claudio Mussolino, Toni Cathomen, Marina Kleanthous and Carsten Werner Lederer*, <i>Front Genome Ed.</i> 2023 Mar 8;5:1141618. doi: 10.3389/fgeed.2023.1141618. eCollection 2023.</p> <p><i>Catching Them Early: Framework Parameters and Progress for Prenatal and Childhood Application of Advanced Therapies</i><br/>Carsten W. Lederer, Lola Koniali, Tina Buerki-Thurnherr, <b>Panayiota L. Papisavva</b>, Stefania La Grutta, Amelia Licari, Frantisek Staud, Donato Bonifazi, and Marina Kleanthous. <i>Pharmaceutics.</i> 2022;14(4):793. <a href="https://doi.org/10.3390/pharmaceutics14040793">https://doi.org/10.3390/pharmaceutics14040793</a></p> |
|---------------------------------------|--|

*CRISPR Editing Enables Consequential Tag-Activated MicroRNA-Mediated Endogene Deactivation.*

**Panayiota L. Papasavva**, Petros Patsali , Constantinos C. Loucari, Ryo Kurita, Yukio Nakamura, Marina Kleanthous, Carsten W. Lederer. *Int J Mol Sci.* 2022, 23(3):1082. <https://doi.org/10.3390/ijms23031082>

*Distinct miRNA Signatures and Networks Discern Fetal from Adult Erythroid Differentiation and Primary from Immortalized Erythroid Cells*

**Panayiota L. Papasavva**, Nikoletta Y. Papaioannou, Petros Patsali, Ryo Kurita, Yukio Nakamura, Maria Sitarou, Soteroulla Christou, Marina Kleanthous, and Carsten W. Lederer. *Int. J. Mol. Sci.* 2021, 22(7):3626, <https://doi.org/10.3390/ijms22073626>

*Relative and absolute quantification of aberrant and normal splice variants in HBBIVSI-110(G>A)  $\beta$ -thalassemia*

Petros Patsali, **Panayiota Papasavva**, Soteroulla Christou, Maria Sitarou, Michael N. Antoniou, Carsten W. Lederer \*, Marina Kleanthous *Int. J. Mol. Sci.* 2020, 21(18), 6671; doi: 10.3390/ijms21186671

*Genetic Modifiers at the Crossroads of Personalised Medicine for Haemoglobinopathies.*

Coralea Stephanou, Stella Tamana, Anna Minaidou, **Panayiota Papasavva**, Marina Kleanthous and Petros Kountouris. *J. Clin. Med.* 2019, 8(11), 1927; <https://doi.org/10.3390/jcm8111927>

*Gene Therapy Getting Personal: Mutation-Specific Editing and Gene Addition Strategies for  $\beta$ -Thalassaemia*

Carsten W. Lederer, Petros Patsali, **Panayiota Papasavva**, Coralea Stephanou, Giandomenico Turchiano, Petros Ladas, Argyro Floga, Soteroulla Christou, Maria Sitarou, Annita Kolagnou, Claudio Mussolino, Tatjana I. Cornu, Michael N. Antoniou, Toni Cathomen, Marina Kleanthous *Hemoglobin*, 2019, 43(6):330-330, <https://doi.org/10.1080/03630269.2020.1719599>

*Correction of IVS I-110(G>A) beta-thalassemia by CRISPR/Cas- and TALEN-mediated disruption of aberrant regulatory elements in human hematopoietic stem and progenitor cells*

Petros Patsali, Giandomenico Turchiano, **Panayiota Papasavva**, Marianna Romito, Constantinos C. Loucari, Coralea Stephanou, Soteroulla Christou, Maria Sitarou, Claudio Mussolino, Tatjana I. Cornu, Michael N. Antoniou, Carsten W. Lederer, Toni Cathomen, Marina Kleanthous. *Haematologica* 2019 April. doi:10.3324/haematol.2018.215178 (2019)

*Rare opportunities: CRISPR/Cas9-based therapy development for rare genetic diseases.*

**Papasavva P**, Kleanthous M, Lederer CW. *Mol. Diagnosis Ther.* 23, 201–222 (2019); <https://doi.org/10.1007/s40291-019-00392-3>

*Short-hairpin RNA against aberrant HBBIVSI-110(G>A) mRNA restores  $\beta$ -globin levels in a novel cell model and acts as mono- and combination therapy for  $\beta$ -thalassemia in primary hematopoietic stem cells*

Patsali P, **Papasavva P**, Stephanou C, Christou S, Sitarou M, Antoniou M, Lederer CW, Kleanthous M. *Haematologica* 2018 Apr 26. doi: 10.3324/haematol.2018.189357. PMID: 29700171

*Rapid and sensitive assessment of globin chains for gene and cell therapy of haemoglobinopathies*

Loucari CC, Patsali P, van Dijk TB, Stephanou C, **Papasavva P**, Zanti M, Kurita R, Nakamura Y, Christou S, Sitarou M, Philipsen S, Lederer CW, Kleanthous M. *Hum Gene Ther Methods.* 2018 Jan 12. doi: 10.1089/hgtb.2017.190

*Suitability of Small Diagnostic Peripheral-blood Samples for Cell-therapy Studies.*

Stephanou C, **Papasavva P**, Zachariou M, Patsali P, Epitropou M, Ladas P, Al-Abdulla R, Christou S, Antoniou MN, Lederer CW, Kleanthous M. *Cytotherapy.* 2017 Feb;19(2):311-326. doi: 10.1016/j.jcyt.2016.11.007. PMID: 28088294

### Oral presentations/Invited talks

1. *Genetic predisposition to Myeloid neoplasms*, Pancyprian Antileukemia Association ZOE conference on “Hematological disorders”, 10/09/2022, Nicosia, Cyprus. **Invited talk.**
2. **Panayiota L. Papasavva**, Nikoletta Y. Papaioannou, Petros Patsali, Constantinos C. Loucari, Ryo Kurita, Yukio Nakamura, Marina Kleanthous, and Carsten W. Lederer, 27/05/2022, *Exploring Erythroid miRNA Signatures and Silencing of Gamma-globin Repressors by Engineered miRNA-dependent Endogene Deactivation*, 5th Congress of the Hellenic Society of Gene Therapy and Regenerative Medicine, 27-29 May, 2022, Thessaloniki, Greece. **Oral Presentation.**
3. **Papasavva P**, Papaioannou Y. N., Patsali P., Sitarou M., Christou S., Lederer CW, Kleanthous M. 05/12/2020 *Characterization of miRNA expression during erythropoiesis*, 8th International Conference of the Cyprus Society of Human Genetics, Virtual meeting. **Oral Presentation.**
4. **Papasavva P**, Patsali P, Lederer CW, Kleanthous M. 06/11/2019 *Characterization of small non-coding RNA expression during erythropoiesis*. 7th International Multithematic Bio-Medical Congress, Nicosia, Cyprus. **Poster and Oral Presentation.**
5. **Papasavva P**, Patsali P, Loucari CC, Obaid M, Stais E, Lederer CW, Kleanthous M. 08/12/2018 *Functional analysis of CRISPR/Cas9-based disruption of beta thalassemia disease modifiers*. 7th International Conference of the Cyprus Society of Human Genetics, Nicosia, Cyprus. **Poster and Oral Presentation.**
6. **Papasavva, P**; Vlachos, P; Roussou, P. 16/04/2011 *Chronic lymphocytic leukaemia in a patient with polycythaemia vera: An interesting co-existence*. Haematology department of the 3<sup>rd</sup> University Clinic of Athens Hospital “Sotiria”, Days of Internal Medicine, Athens. **Poster and Oral Presentation.**

### Posters as presenting author

1. **P Papasavva**, NY Papaioannou, L Koniali, B Naisseh, S Christou, M Sitarou, MN Antoniou, T Cathomen, M Kleanthous\*, CW Lederer\*, P Patsali\*. *Evaluation of induction of fetal hemoglobin synthesis by genome editing of cis- and trans-acting components of the  $\beta$ -globin locus*. Poster; 9th CSHG CONFERENCE, March 17-18, 2023, Nicosia, Cyprus
2. **Panayiota L. Papasavva**, Nikoletta Y. Papaioannou, Lola Koniali, Basma Naisseh, Soteroula Christou, Maria Sitarou, Michael N. Antoniou, Toni Cathomen, Marina Kleanthous, Carsten W. Lederer, Petros Patsali, *Evaluation of induction of fetal hemoglobin synthesis by genome editing of cis- and trans-acting components of the  $\beta$ -globin locus*, 10th IMBMC Medical Congress, Nov 3-5, 2022, Nicosia, Cyprus.
3. **Panayiota L. Papasavva**, Nikoletta Y. Papaioannou, Lola Koniali, Basma Naisseh, Soteroula Christou, Maria Sitarou, Michael N. Antoniou, Toni Cathomen, Marina Kleanthous, Carsten W. Lederer, Petros Patsali, *Evaluation of induction of fetal hemoglobin synthesis by genome editing of cis- and trans-acting components of the  $\beta$ -globin locus*, 1st βιοϕ-SBSCy National Conference on Molecular Life Sciences, 2223 Oct 2022, Nicosia, Cyprus.
4. **Panayiota L. Papasavva**, Nikoletta Y. Papaioannou, Petros Patsali, Constantinos C. Loucari, Ryo Kurita, Yukio Nakamura, Marina Kleanthous, and Carsten W. Lederer. *Exploring Erythroid miRNA Signatures and Silencing of Gamma-globin Repressors by Engineered miRNA-dependent Endogene Deactivation*, IUBMB Focused Meeting – Hemoglobin Switching, May 5<sup>th</sup> to 9<sup>th</sup>, 2022, Crete, Greece. **Poster.**
5. **Panayiota L. Papasavva**, Petros Patsali, Constantinos C. Loucari, Lola Koniali, Nikoletta Y. Papaioannou, Basma Naisseh, Marina Kleanthous, and Carsten W. Lederer, *Exploring miRNAs as tools for therapy: Tag-activated microRNA-mediated endogene deactivation (TAMED)*, 9<sup>th</sup> IMBMC congress, Nov 18<sup>th</sup> to 20<sup>th</sup>, 2021, Nicosia, Cyprus, **1<sup>st</sup> Prize for Best Poster.**



6. **Panayiota L. Papasavva**, Petros Patsali, Constantinos C. Loucari, Lola Koniali, Nikoletta Y. Papaioannou, Basma Naisseh, Marina Kleanthous, and Carsten W. Lederer, *Exploring miRNAs as tools for therapy: Tag-activated microRNA-mediated endogene deactivation (TAMED)*, TIF 2021 International Conference, Nov 19<sup>th</sup> to 21<sup>st</sup> ,2021. **Poster.**
7. **Papasavva P**, Papaioannou NY, Patsali P, Christou S, Sitarou M, Lederer CW, Kleanthous M. 26/10/2020 *Characterisation of small non-coding RNAs during erythropoiesis*. ASCAT Conference 2020, Virtual global conference. **Poster.**
8. **Papasavva P**, Patsali P, Lederer CW, Kleanthous M. 06/11/2019 *Characterization of small non-coding RNA expression during erythropoiesis*. 7<sup>th</sup> International Multithematic Bio- Medical Congress, Nicosia, Cyprus. **Poster and Oral Presentation.**
9. **Papasavva P**, Patsali P, Loucari CC, Obaid M, Stais E, Lederer CW, Kleanthous M. 15/03/2019 *CRISPR/Cas9-based disruption of beta-thalassaemia disease modifiers*. ESH 1<sup>st</sup> International Conference on Erythropoiesis Control and Ineffective Erythropoiesis: from bench to bedside. Budapest, Hungary. **Poster.**
10. **Papasavva P**, Patsali P, Loucari C, Obaid M, Stais E, Lederer CW, Kleanthous M. 17/11/2018 *CRISPR/Cas9-based disruption of beta-thalassaemia disease modifiers*. **3<sup>rd</sup> Prize for Best Poster.** 6<sup>th</sup> International Multithematic Bio-Medical Congress, Nicosia, Cyprus. **Poster.**
11. Patsali, P, **Papasavva P**, Stephanou C, Christou S, Sitarou M, Antoniou M, Lederer CW<sup>\*\*</sup>, Kleanthous M., *Less means more: knockdown of aberrant HBB<sup>IVS1-110(G>A)</sup> mRNA restores HBB expression and enhances gene therapy by gene addition in primary erythroid cells*, Cyprus Society of Human Genetics, 6<sup>th</sup> International Conference, 24-25 Nov 2017, Nicosia, Cyprus. **Poster.**
12. **Papasavva, P**; Vlachos, P; Roussou, P. 16/04/2011 Chronic lymphocytic leukaemia in a patient with polycythaemia vera: An interesting co-existence. Haematology department of the 3<sup>rd</sup> University Clinic of Athens Hospital "Sotiria", Days of Internal Medicine, Athens. **Poster and Oral Presentation.**

#### **Co-authorship for further posters and presentations**

1. P Patsali, N Psatha, K Paschoudi, **P Papasavva**, NY Papaioannou, B Naisseh, P Christofi, S Christou, M Sitarou, A Pirovolaki, M Hadjigabriel, T Athanasopoulos, T Cathomen, M Kleanthous, E Yannaki, CW Lederer. *Preclinical validation of HBB<sup>IVS1-110(G>A)</sup>-specific gene editing as advanced therapy for thalassemia*. Selected Abstract for Oral Presentation. 9<sup>th</sup> CSHG CONFERENCE, March 17-18, 2023, Nicosia, Cyprus
2. NY Papaioannou, P Patsali, **PL Papasavva**, CW Lederer, M Kleanthous. *Genome editing for beta-haemoglobinopathies without double-strand DNA cleavage*. Selected Abstract for Oral Presentation. 9<sup>th</sup> CSHG CONFERENCE, March 17-18, 2023, Nicosia, Cyprus
3. B Naisseh, NY Papaioannou, **P Papasavva**, C Lardou, M Sitarou, S Christou, CW Lederer\*, M Kleanthous\*, P Patsali\*. *HBB<sup>IVS1-110(G>A)</sup>-specific gene editing as advanced therapy for  $\beta$ -thalassemia*. **Poster**; 9<sup>th</sup> CSHG CONFERENCE, March 17-18, 2023, Nicosia, Cyprus
4. Papaioannou NY, Patsali P, **Papasavva P**, Lola Koniali, Basma Naisseh, Soteroula Christou, Lederer CW, Kleanthous M. *Genome editing for Beta-Haemoglobinopathies Without Double-Strand DNA Cleavage*, IMBMC Medical Congress, Nov 3-5, 2022, Nicosia, Cyprus. **Poster.**
5. Basma Naisseh, Papaioannou NY, **Papasavva P**, Chara Lardou, Maria Sitarou, Soteroula Christou, Lederer CW, Kleanthous M. Patsali P. *HBB IVS I-110(G>A)-specific gene editing as advanced therapy for  $\beta$ -thalassemia*. IMBMC Medical Congress, Nov 3-5, 2022, Nicosia, Cyprus. **Poster.**
6. Lola Koniali, Petros Patsali, Markela I. Kostopoulou, Nikoletta Y. Papaioannou, **Panayiota L. Papasavva**, Basma Naisseh, Coralea Stephanou, Anthi Demetriadou, Maria Sitarou, Soteroula Christou, Toni Cathomen, Michael N. Antoniou, Marina Kleanthous Carsten W. Lederer. *Towards mutation-specific correction of IVS I-110(G>A)-thalassemia using HBB GLOBE-based miR-30-shRNA expression vectors for shRNA mono- and combination therapy*. IMBMC Medical Congress, Nov 3-5, 2022, Nicosia, Cyprus. **Poster.**

7. P Patsali, **P Papasavva**, C Mussolino, NY Papaioannou, B Naiisseh, S Christou, M Sitarou, MN Antoniou, T Cathomen, M Kleanthous, CW Lederer. *Optimisation of personalised TALEN- and CRISPR/Cas9-based gene correction therapy for  $\beta$ -thalassaemia*. **Oral presentation**, 1<sup>st</sup>  $\beta$ loc-SBSCy National Conference on Molecular Life Sciences, 22-23 Oct 2022, Nicosia, Cyprus
8. Basma Naiisseh, Papaioannou NY, **Papasavva P**, Chara Lardou, Maria Sitarou, Soteroulla Christou, Lederer CW, Kleanthous M. Patsali P. *HBB IVS I-110(G>A)-specific gene editing as advanced therapy for  $\beta$ -thalassemia*, European Society of Gene and Cell Therapy, 11–12 October 2022, Edinburgh, Scotland. **Poster**.
9. Patsali P, **Papasavva PL**, Mussolino C, Papaioannou NY, Naiisseh B, Christou S, Sitarou M, Antoniou MN, Cathomen T, Kleanthous M, Lederer CW. *Optimisation of mutation-specific TALEN- and CRISPR/Cas9-based gene correction therapy for  $\beta$ -thalassaemia*, European Society of Gene and Cell Therapy, Edinburgh, UK. In-person. **Poster**.
10. Papaioannou NY, Patsali P, **Papasavva P**, Lola Koniali, Basma Naiisseh, Soteroula Christou, Lederer CW, Kleanthous M. *Genome editing for Beta-Haemoglobinopathies Without Double-Strand DNA Cleavage*, European Human Genetics Conference, 11–14 June 2022, Vienna, Austria. **Poster**.
11. Papaioannou NY, Patsali P, **Papasavva P**, Lola Koniali, Basma Naiisseh, Soteroula Christou, Lederer CW, Kleanthous M. *Genome editing for Beta-Haemoglobinopathies Without Double-Strand DNA Cleavage*, 5th Congress of the Hellenic Society of Gene Therapy and Regenerative Medicine, 27-29 May, 2022, Thessaloniki, Greece
12. Papaioannou NY, Patsali P, **Papasavva P**, Lola Koniali, Basma Naiisseh, Soteroula Christou, Lederer CW, Kleanthous M. *Genome editing for Beta-Haemoglobinopathies Without Double-Strand DNA Cleavage*, IUBMB Focused Meeting – Hemoglobin Switching, May 5th to 9th, 2022, Crete, Greece. **Poster**.
13. Lola Koniali, Petros Patsali, Markela I. Kostopoulou, Nikoletta Y. Papaioannou, **Panayiota L. Papasavva**, Basma Naiisseh, Coralea Stephanou, Anthi Demetriadou, Maria Sitarou, Soteroulla Christou, Toni Cathomen, Michael N. Antoniou, Marina Kleanthous Carsten W. Lederer. *Towards mutation-specific correction of IVS I-110(G>A)-thalassemia using HBB GLOBE-based miR-30-shRNA expression vectors for shRNA mono- and combination therapy*, IUBMB Focused Meeting – Hemoglobin Switching, May 5th to 9th, 2022, Crete, Greece. **Poster**.
14. Petros Patsali, Giandomenico Turchiano, **Panayiota Papasavva**, Marianna Romito, Constantinos C. Loucari, Coralea Stephanou, Soteroulla Christou, Maria Sitarou, Claudio Mussolino, Tatjana I. Cornu, Michael N. Antoniou, Carsten W. Lederer, Toni Cathomen, Marina Kleanthous. *Optimisation of personalized TALEN- and CRISPR/Cas9-based gene correction therapy for  $\beta$ -thalassemia on patient-derived primary cells towards clinical translation*, IUBMB Focused Meeting – Hemoglobin Switching, May 5th to 9th, 2022, Crete, Greece. **Poster**.
15. Basma Naiisseh, Papaioannou NY, **Papasavva P**, Chara Lardou, Maria Sitarou, Soteroulla Christou, Lederer CW, Kleanthous M. Patsali P. *HBB IVS I-110(G>A)-specific gene editing as advanced therapy for  $\beta$ -thalassemia*, IUBMB Focused Meeting – Hemoglobin Switching, May 5th to 9th, 2022, Crete, Greece. **Poster**.
16. Papaioannou NY, Patsali P, **Papasavva P**, Lederer CW, Kleanthous M. 04-05/12/2020 *Genome Editing for Beta-Haemoglobinopathies Without Double-Strand DNA Cleavage*, 8<sup>th</sup> International Conference of the Cyprus Society of Human Genetics, Virtual meeting, **Poster**.
17. Lederer CW, Patsali P, **Papasavva P**, Stephanou C, Turchiano G, Romito M, Christou S, Sitarou M, Mussolino C, Cornu TI, Antoniou MN, Cathomen T, Kleanthous M. 25/11/2019 *Gene Therapy Getting Personal: mutation-specific editing and gene addition strategies*. RESTORE 1<sup>st</sup> Advanced Therapies Science Meeting, Berlin, Germany. **Oral Presentation**.
18. Lederer CW, Patsalis P, **Papasavva P**, Stephanou C, Turchiano G, Romito M, Christou S, Sitarou M, Mussolino C, Cornu TI, Antoniou MN, Cathomen T, Kleanthous M. 07/11/2019 *Getting personal: mutation-specific gene editing and addition strategies for  $\beta$ -thalassemia and beyond*. 7<sup>th</sup> International Multithematic Bio-Medical Congress, Nicosia, Cyprus. **Poster and Oral Presentation. Best Poster Award, 1<sup>st</sup> Prize**.

19. Lederer CW, Patsali P, **Papasavva P**, Stephanou C, Turchiano G, Romito M, Christou S, Sitarou M, Mussolino C, Cornu TI, Antoniou MN, Cathomen T, Kleanthous M. 30/10/2019 *Getting personal: mutation-specific gene editing and addition strategies for  $\beta$ -thalassemia and beyond*. Global Globin 2020 Annual Conference. UNESCO Paris, France. **Invited Lecture**.
20. Lederer CW, Patsali P, **Papasavva P**, Felisi M, Kleanthous M. 25/11/2019 *Catching them early: ethics and economy of prenatal and childhood application of ATMPs*. RESTORE 1<sup>st</sup> Advanced Therapies Science Meeting. Berlin, Germany. **Poster**.
21. Patsalis P, Turchiano G, **Papasavva P**, Romito M, Loucari C, Stephanou C, Christou S, Sitarou M, Mussolino C, Cornu TI, Antoniou MN, Lederer CW, Cathomen T, Kleanthous M. 06/11/2019 *Optimisation of personalized TALEN- and CRISPR/Cas9-based gene correction therapy for  $\beta$ -thalassaemia on patient-derived primary cells towards clinical translation*. 7<sup>th</sup> International Multithematic Bio-Medical Congress, Nicosia, Cyprus. **Poster**.
23. Lederer CW, Patsalis P, **Papasavva P**, Stephanou C, Turchiano G, Romito M, Christou S, Sitarou M, Mussolino C, Cornu TI, Antoniou MN, Cathomen T, Kleanthous M. 25/10/2019 *Getting personal: mutation-specific gene editing and addition strategies for  $\beta$ -thalassemia and beyond*. European Society of Gene and Cell Therapy. Barcelona, Spain. **Poster**.
24. Patsalis P, Turchiano G, **Papasavva P**, Romito M, Loucari CC, Stephanou C, Christou C, Sitarou M, Mussolino C, Cornu TI, Antoniou MN, Lederer CW<sup>†</sup>, Cathomen C, Kleanthous M. 15/06/2019 *Safe and efficient personalized TALEN- and CRISPR/Cas9-based gene correction therapy for  $\beta$ -thalassaemia by non-viral delivery to primary cells*. <https://www.nature.com/articles/s41431-019-0492-4>. European Society of Human Genetics 52<sup>nd</sup> Annual Conference, Gothenburg. Sweden. **Oral Presentation/CSHG&ESHG National Fellowship Award**.
25. Lederer CW, Patsali P, **Papasavva P**, Loucari CC, Obaid M, Stais E, Stephanou C, Turchiano G, van Dijk T, Romito M, Christou C, Sitarou M, Mussolino C, Cornu TI, Antoniou MN, Philipsen S, Cathomen C, Kleanthous M. 17/05/2019 *Application of homology-independent gene editing strategies for  $\beta$ -thalassemia*. 4<sup>th</sup> Congress of the Hellenic Society for Gene Therapy and Regenerative Medicine. Athens, Greece. **Poster**.
26. Lederer CW, Patsali P, **Papasavva P**, Kleanthous M. 17/11/2018 *Gene editing for genetic disorders: therapy development in the fast lane*. 6<sup>th</sup> International Multithematic Bio- Medical Congress. Nicosia, Cyprus. **Poster**.
27. Patsali P, **Papasavva P**, Romito M, Turchiano G, Loucari C, Stephanou C, Christou S, Sitarou M, Cornu TI, Mussolino C, Antoniou MN, Cathomen T<sup>†</sup>, Lederer CW<sup>†</sup>, Kleanthous M<sup>†</sup>. 17/11/2018 *CRISPR/Cas9- and TALEN-mediated disruption of aberrant regulatory elements restores normal splicing and gene function*. 6<sup>th</sup> International Multithematic Bio- Medical Congress, Nicosia, Cyprus. **Poster and Oral Presentation**.
28. Patsali P, **Papasavva P**, Romito M, Turchiano G, Loucari C, Stephanou C, Christou S, Sitarou M, Cornu TI, Mussolino C, Antoniou MN, Cathomen T<sup>†</sup>, Lederer CW, Kleanthous M. 16/10/2018 *CRISPR/Cas9- and TALEN-mediated disruption of aberrant regulatory elements restores normal splicing and gene function*. European Society of Gene and Cell Therapy, Lausanne, Switzerland. **Poster**.
29. Loucari C, van Dijk TB, Patsali P, **Papasavva P**, Sitarou M, Christou S, Philipsen S, Lederer, CW, Kleanthous, M. 16/10/2018 *Reversal of fetal globin silencing in primary cells through isoform-specific knockout of the BCL11A transcription factor*. European Society of Gene and Cell Therapy, Lausanne, Switzerland. **Poster**.
30. Loucari C, van Dijk TB, Patsali P, **Papasavva P**, Phylactides MS, Sitarou M, Christou S, Philipsen S, Lederer, CW, Kleanthous, M. 16/09/2018 *Reversal of fetal globin silencing in primary cells through isoform-specific knockout of the BCL11A transcription factor*. 21<sup>st</sup> Hemoglobin Switching Meeting. **Poster**.



31. Patsali P, **Papasavva P**, Romito M, Turchiano G, Loucari C, Stephanou C, Christou S, Sitarou M, Cornu TI, Mussolino C, Antoniou MN, Cathomen T, Lederer CW, Kleanthous M. 02/06/2018 *CRISPR/Cas9 and TALEN-mediated disruption of aberrant splice site restores normal gene function*. 3<sup>rd</sup> Congress of the Hellenic Society for Gene Therapy and Regenerative Medicine, Thessaloniki, Greece. **Oral Presentation. George Stamatoyiannopoulos Prize for best original research.**
32. Loucari C; van Dijk TB; Patsali P, **Papasavva P**, Sitarou M, Christou S, Philipsen S; Lederer, CW\*; Kleanthous, M\*, *Isoform-specific disruption of the BCL11A transcription factor*. Cyprus Society of Human Genetics, 6<sup>th</sup> International Conference, 24-25 Nov 2017, Nicosia, Cyprus. **Poster.**
33. Patsali, P, Mussolino C, **Papasavva P**, Turchiano G, Romito M, Loucari C, Stephanou C, Christou S, Sitarou M, Cornu T, Antoniou M, Cathomen T, Lederer CW\*+, Kleanthous M. *Gene Correction at Clinically Relevant Efficiencies by Non-viral Delivery and Disruption of an Aberrant Regulatory Element*. Cyprus Society of Human Genetics, 6<sup>th</sup> International Conference, 24-25 Nov 2017, Nicosia, Cyprus. **Poster.**
34. Topouzoglou, Z; Galanopoulos, A; Bakarakos, P; Papasavva, P; Minakakis, I; Leveta, G; Marinakis, Th; Papadaki, Ch; Gortzolidis, G; Anagnostopoulos, N.I. 24/11/2012 *Brain Pseudotumor syndrome in a patient with acute promyelocytic leukaemia*. 23<sup>rd</sup> National Haematology Congress, Thessaloniki, Greece. **Poster.**
35. Goumakou, E; Papademetriou, S.I.; Paterakis, G; **Papasavva, P**; Tsangarakis, N; Androutsos, G; Pavlides, D; Marinakis, Th; Gortzolidis, G; Michali, E; Anagnostopoulos, N.I; Kritikou- Griva. 24/11/2012 *Differential diagnosis of Burkitt lymphoma in adults*. Hematologic Laboratory, Immunology Laboratory, Haematology Clinic, G. Gennimatas Hospital, Athens, Greece 23<sup>rd</sup> National Haematology Congress, Thessaloniki, Greece. **Poster.**
36. Marinakis, Th; Savvidou, N; Kannavos, G; Giannopoulos, V; Galanopoulos, A; Michali, E; Gortzolidis, G; Papadaki, Ch; Minakakis, I; **Papasavva, P**; Goumakou, E; Griva, E; Georgiakaki, M; Paterakis, G; Grigoraki, V; Anagnostopoulos, N.I. 26/11/2011 *Treatment of acute myelocytic leukaemia in patients >60 years old with the administration of mitoxantrone- aracytine combination. Ten years' experience of a tertiary centre*. Haematology Clinic and Immunology Laboratory, G. Gennimatas Hospital, Athens, Greece, 22<sup>nd</sup> National Haematology Congress, Athens, Greece. **Poster.**
37. Kontonis, I; Marinakis, Th; Papadopoulos, V; Savvidou, N; Kannavos, G; Leveta, G; Topouzoglou, Z; Minakakis, I; Bakarakos, P; **Papasavva, P**; Anagnostopoulos, N. 21/05/2011 *Treating patients with idiopathic thrombocytosis; 10 years' experience from a Haematology centre*. Haematology Clinic, G. Gennimatas Hospital, Athens, Greece, Haematology Clinic, "Papageorgiou" Hospital, Thessaloniki, Greece 37<sup>th</sup> National Medical Congress, Athens, Greece. **Poster.**
38. Petropoulos, F; Merikas, E; Adamopoulos, A; Kaitsa, E; Karakatsanis, S; **Papasavva, P**; Roussou, P. 07/11/2009 *Gastrointestinal lymphomas: Retrospective study*. Haematology department of the 3<sup>rd</sup> University Clinic of Athens Hospital "Sotiria", 20<sup>th</sup> National Haematology Congress, Heracleion, Crete, Greece. **Poster.**
39. Kaitsa, E; Karakatsanis, S; **Papasavva, P**; Roussou, P. 07/11/2009 *Epidemiologic characteristics and clinical course of patients with myelodysplastic syndrome: 17 years' experience of the haematology department of the 3<sup>rd</sup> University Clinic of Athens Hospital "Sotiria"*, 20<sup>th</sup> National Haematology Congress, Heracleion, Crete, Greece. **Poster.**
40. Karakatsanis, S; Kaitsa, E; **Papasavva, P**; Katsigiannis, A; Giannopoulos, K; Roussou, P. 07/11/2009 *Diffuse Large B-cell Lymphoma: Epidemiologic characteristics and effectiveness of current therapeutic strategies in a Tertiary Hospital specializing in thoracic diseases*. Haematology department of the 3<sup>rd</sup> University Clinic of Athens Hospital "Sotiria", 20<sup>th</sup> National Haematology Congress, Heracleion, Crete, Greece. **Poster.**

41. Kaitsa, E; Karakatsanis, S; **Papasavva, P**; Petropoulos, F; Markatos, C; Roussou, P. 07/11/2009 *Hodgkin's disease: 15 years' experience*, Haematology department of the 3<sup>rd</sup> University Clinic of Athens Hospital "Sotiria", 20<sup>th</sup> National Haematology Congress, Heracleion, Crete, Greece. **Poster.**
42. C.Petrogiannopoulos, G.Svoukas, K.Papamichael, A.Deliouis, K.Kanakis, **P.Papasavva**, N.Kostakos, A.Zaharof, 05/04/2005, *Ertapenem as initial antimicrobial monotherapy for patients with typical community-acquired pneumonia*, 2<sup>nd</sup> Department of Internal Medicine, Hellenic Red Cross Hospital, Athens, Greece, 15<sup>th</sup> European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). **Poster.**